Gsk Plc ADR (GSK): Congress and insider trades
Who in Congress and inside the company traded GSK, when each filing appeared, and what buying after each one would have earned against the S&P 500.
Key Facts
- Gsk Plc ADR (GSK) is a listed stock on NYSE.
- 7 members of Congress filed 16 buys and 8 sells of GSK, the latest published 2026-07-21 (21 July 2026).
- Across 10 scored buys, Congress averaged +1.5% against the S&P 500 (SPY) over the 90 days after disclosure, with 60% of them ahead of the index. That result is not distinguishable from luck.
- Data as of 2026-09-29 (29 September 2026).
Congress trades in GSK
as of 2026-07-21| Filed | Member | Type | Size | Days to file | 90 day vs S&P |
|---|---|---|---|---|---|
| 21 Jul 2026 | Alan Armstrong (R-OK) | buy | 15K–50K | 113 | n/a |
| 13 May 2025 | Bruce Westerman (R-AR) | sell | 1K–15K | 21 | n/a |
| 16 Nov 2023 | Tommy Tuberville (R-AL) | sell | 1K–15K | 31 | n/a |
| 14 Aug 2023 | Daniel S. Goldman (D-NY) | sell | 15K–50K | 34 | n/a |
| 12 May 2023 | Tommy Tuberville (R-AL) | buy | 1K–15K | 39 | -11.3% |
| 5 Apr 2023 | Virginia Foxx (R-NC) | sell | 50K–100K | 34 | n/a |
| 9 Sep 2022 | Virginia Foxx (R-NC) | buy | 1K–15K | 30 | +15.8% |
| 9 Sep 2022 | Virginia Foxx (R-NC) | buy | 15K–50K | 34 | +15.8% |
| 9 Sep 2022 | Virginia Foxx (R-NC) | buy | 15K–50K | 29 | +15.8% |
| 9 Sep 2022 | Virginia Foxx (R-NC) | buy | 1K–15K | 23 | +15.8% |
| 8 Aug 2022 | Virginia Foxx (R-NC) | sell | 100K–250K | 24 | n/a |
| 8 Aug 2022 | Virginia Foxx (R-NC) | buy | 1K–15K | 30 | -12.0% |
| 5 May 2022 | Virginia Foxx (R-NC) | buy | 1K–15K | 26 | -8.3% |
| 17 Mar 2022 | John Rutherford (R-FL) | sell | 1K–15K | 27 | n/a |
| 8 Mar 2022 | Virginia Foxx (R-NC) | buy | 1K–15K | 13 | +10.3% |
| 7 Feb 2022 | Virginia Foxx (R-NC) | buy | 1K–15K | 21 | +8.3% |
| 3 Nov 2021 | Virginia Foxx (R-NC) | buy | 1K–15K | 25 | +9.3% |
| 16 Aug 2021 | Katherine Clark (D-MA) | sell | 1K–15K | 72 | n/a |
| 3 Aug 2021 | Virginia Foxx (R-NC) | buy | 1K–15K | 24 | +1.5% |
| 6 May 2021 | Virginia Foxx (R-NC) | buy | 1K–15K | 26 | +3.2% |
| 2 Feb 2021 | Virginia Foxx (R-NC) | buy | 1K–15K | 17 | -1.4% |
| 29 Dec 2020 | Katherine Clark (D-MA) | buy | 1K–15K | 53 | n/a |
| 4 Dec 2020 | Katherine Clark (D-MA) | sell | 1K–15K | 42 | n/a |
| 7 Nov 2020 | Virginia Foxx (R-NC) | buy | 1K–15K | 28 | n/a |
Nothing matches that search.
Related pages
Frequently asked questions
Who has bought GSK?
16 Congress buys by 7 members and 0 insider buys are on file. The tables on this page list every one.
Did buying GSK after a disclosure beat the market?
Across 10 scored buys, Congress averaged +1.5% against the S&P 500 (SPY) over the 90 days after disclosure, with 60% of them ahead of the index. That result is not distinguishable from luck. A single stock is a small sample.
Sources: Congressional trades: STOCK Act disclosures, collected from CapitolTrades. Insider trades: SEC Form 4 filings, collected from Finviz. Prices: Yahoo Finance daily adjusted closes. Data as of 2026-09-29 (29 September 2026). About these sources.
Not investment advice. Past disclosed trades do not predict future returns. Disclosures are published late, so the trades shown are ones you could only have copied after the fact. Talk to a licensed adviser before you invest.